In addition, the company announced that James Lock will not stand for re-election as a director on the company’s board of directors. Mr Lock will continue to work with the company as an unpaid advisor on NMT’s newly formed scientific advisory board. As a result, NMT will reduce the number of seats on its board to five.
James Mahoney, Jr, chairman of the board of NMT Medical, said: “Frank exudes every quality we were looking for in our executive search, most importantly a strong background in sales and marketing and an impressive track record of success in heading-up interventional cardiology companies and divisions over many years.
“He is an exceptional leader who has been working closely with the company since joining the board in 2001. We are delighted that he accepted the longer-term leadership position at NMT.”